Novel Triple Combination Regimen for Treating TB

A combination of moxifloxacin, pretomanid, and pyrazinamide showed significantly greater bactericidal activity than the standard four-drug regimen for treating drug-susceptible tuberculosis.

Drug options for treating tuberculosis (TB) are limited. Investigators conducted a phase IIb study at eight sites in South Africa and Tanzania comparing a new regimen — moxifloxacin, pretomanid (previously known as PA-824), and pyrazinamide (MPaZ) —with the standard four-drug regimen (isoniazid, rifampin, pyrazinamide, and ethambutol; HRZE) for treating patients with smear-positive pulmonary TB. They included HIV-infected patients if they had CD4 counts >200 cells/mm³; they excluded patients with extrapulmonary TB or cardiac arrhythmias.

Participants with drug-susceptible TB (n=181) were randomized to one of three groups: the three-drug regimen with 100 mg of pretomanid (MPa100Z), the same with 200 mg pretomanid (MPa200Z), or the standard HR…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Novel Triple Combination Regimen for Treating TB

Topics

Reviewing Author